n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with prazosin in 8 studies
| Studies (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine) | Trials (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine) | Recent Studies (post-2010) (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine) | Studies (prazosin) | Trials (prazosin) | Recent Studies (post-2010) (prazosin) |
|---|---|---|---|---|---|
| 214 | 5 | 58 | 7,914 | 713 | 682 |
| Protein | Taxonomy | n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine (IC50) | prazosin (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 5.87 | |
| Interstitial collagenase | Homo sapiens (human) | 4.036 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 2.638 | |
| Matrix metalloproteinase-9 | Homo sapiens (human) | 6.963 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0008 | |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 0.0078 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.29 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.647 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0008 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.0007 | |
| Bromodomain-containing protein 2 | Homo sapiens (human) | 0.0009 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.0006 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.0006 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 4.118 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0008 | |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | 9.9 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.5849 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartoccini, F; Carminati, P; Castorina, M; Di Cesare, MA; Di Serio, S; Gallo, G; Ghirardi, O; Giorgi, F; Giorgi, L; Minetti, P; Piersanti, G; Tarzia, G; Tinti, MO | 1 |
| Axe, FU; Bembenek, SD; Butler, CR; Coles, F; Dunford, PJ; Edwards, JP; Fourie, AM; Grice, CA; Karlsson, L; Lundeen, K; Riley, JP; Savall, BM; Tays, KL; Wei, J; Williams, KN; Xue, X | 1 |
| Altenbach, RJ; Brioni, JD; Carr, TL; Chandran, P; Cowart, MD; Esbenshade, TA; Honore, P; Hsieh, GC; Lewis, LG; Liu, H; Manelli, AM; Marsh, KC; Milicic, I; Miller, TR; Strakhova, MI; Vortherms, TA; Wakefield, BD; Wetter, JM; Witte, DG | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Carmody, LC; Dandapani, S; Donckele, E; Feng, Y; Fernandez, C; Germain, AR; Gupta, PB; Lander, ES; Morgan, B; Munoz, B; Nag, PP; Palmer, M; Perez, JR; Schreiber, SL; Verplank, L | 1 |
| Anzini, M; Brogi, S; Butini, S; Campiani, G; Cappelli, A; Caselli, G; Castriconi, F; Gemma, S; Giordani, A; Giorgi, G; Giuliani, G; Lanza, M; Letari, O; Makovec, F; Manini, M; Mennuni, L; Valenti, S | 1 |
| Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E | 1 |
| Filipek, B; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pańczyk, K; Pękala, E; Rapacz, A; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D; Żesławska, E | 1 |
8 other study(ies) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and prazosin
| Article | Year |
|---|---|
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Cell Line; Cricetinae; Cricetulus; Drug Design; Humans; Imidazoles; Male; Models, Molecular; Motor Activity; Purines; Radioligand Assay; Rats; Rats, Inbred F344; Structure-Activity Relationship; Triazoles | 2005 |
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Catalysis; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Magnetic Resonance Spectroscopy; Mice; Structure-Activity Relationship | 2008 |
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperalgesia; Ligands; Mice; Molecular Structure; Pain; Peritonitis; Quinazolines; Rats; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Stereoisomerism; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Topics: Amides; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Neoplastic Stem Cells; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
Topics: Animals; Area Under Curve; Humans; Intestinal Absorption; Ligands; Male; Metabolic Clearance Rate; Models, Chemical; Models, Molecular; Molecular Structure; Protein Binding; Protein Structure, Tertiary; Pyrrolidinones; Radioligand Assay; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin, 5-HT3; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship | 2013 |
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Male; Mice; Microsomes, Liver; Molecular Structure; Pilocarpine | 2016 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Mice; Models, Molecular; Molecular Structure; Rats; Seizures; Structure-Activity Relationship | 2017 |